APA (7th ed.) Citation

Azevedo, R. S., Braish, J., Gener-Ricos, G., Tang, G., Sasaki, K., Montalban-Bravo, G., . . . Kadia, T. M. (2026). Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia. Leukemia & Lymphoma, 67(1), 220. https://doi.org/10.1080/10428194.2025.2568745

Chicago Style (17th ed.) Citation

Azevedo, Roberta S., et al. "Cladribine, High-dose Cytarabine, Plus Gemtuzumab Ozogamicin (CLAG-GO) as Frontline Intensive Therapy for Fit Patients with Core-binding Factor Acute Myeloid Leukemia." Leukemia & Lymphoma 67, no. 1 (2026): 220. https://doi.org/10.1080/10428194.2025.2568745.

MLA (9th ed.) Citation

Azevedo, Roberta S., et al. "Cladribine, High-dose Cytarabine, Plus Gemtuzumab Ozogamicin (CLAG-GO) as Frontline Intensive Therapy for Fit Patients with Core-binding Factor Acute Myeloid Leukemia." Leukemia & Lymphoma, vol. 67, no. 1, 2026, p. 220, https://doi.org/10.1080/10428194.2025.2568745.